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Abstract
Height is a classic polygenic trait, reflecting the combined influence of multiple as-yet-
undiscovered genetic factors. We carried out a meta-analysis of genome-wide association study
data of height from 15,821 individuals at 2.2 million SNPs, and followed up the strongest findings
in >10,000 subjects. Ten newly identified and two previously reported loci were strongly
associated with variation in height (P values from 4 × 10-7 to 8 × 10-22). Together, these 12 loci
account for ~2% of the population variation in height. Individuals with ≤8 height-increasing
alleles and ≥16 height-increasing alleles differ in height by ~3.5 cm. The newly identified loci,
along with several additional loci with strongly suggestive associations, encompass both strong
biological candidates and unexpected genes, and highlight several pathways (let-7 targets,
chromatin remodeling proteins and Hedgehog signaling) as important regulators of human stature.
These results expand the picture of the biological regulation of human height and of the genetic
architecture of this classical complex trait.
The advent of genome-wide association studies1, made possible by knowledge gained from
the HapMap Consortium2 and recent advances in genome-wide genotyping technologies
and analytic methods, have had a dramatic impact on the field of human genetics. Recent
genome-wide studies have led to the identification of common genetic variants reproducibly
associated with complex human diseases3. Genome-wide association (GWA) studies have
also been used successfully to identify genetic variation associated with quantitative traits,
such as lipid levels4 and body mass index5,6. These discoveries, through the identification
of previously unknown and often unanticipated genes, have opened an exciting period in the
study of human complex traits and common diseases.
The small effect sizes that have characterized most of the variants recently identified present
a challenge to the study of polygenic diseases and traits, as large sample sizes have generally
been required to identify associated common variants. It is not yet known whether
increasing sample size further will accelerate the pace of discovery, and to what extent
multiple loci with modest effect will reveal previously unsuspected biological pathways. To
begin to answer these important questions, we used adult height as a model phenotype.
Adult height is a complex trait with high heritability (h2 ~0.8-0.9 within individual
populations)7,8. Furthermore, height is accurately measured and relatively stable over a
large part of the lifespan9, and data is available for very large numbers of individuals. Thus,
the study of height is an ideal opportunity to dissect the architecture of a highly polygenic
trait in humans. In addition, because height is associated with several common human
diseases (for example, cancers)10, loci associated with height may be pleiotropic,
influencing the risk or severity of other diseases11.
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Using data from GWA studies, we and our colleagues identified the first two common
variants to be robustly associated with adult height variation: a SNP in the 3′ UTR of the
HMGA2 gene12 and a SNP at the GDF5-UQCC locus11. The overall variation in height
explained by these two polymorphisms is small (0.3-0.7% of the total variance), suggesting
that most common variants that influence height will have a small effect. The modest effects
observed also highlight the importance of using large datasets to identify ‘true’ stature
variants: the HMGA2 SNP was first found in a combined analysis of the DGI and Wellcome
Trust Case Control Consortium UKT2D datasets (n = 4,921 individuals), and the GDF5-
UQCC finding was identified initially in an analysis of the SardiNIA and FUSION results (n
= 6,669 individuals). As these findings are likely to be among the upper range of effect sizes
for common variants associated with height, we considered the likely possibility that
progressively larger sample sizes would be required to identify additional height loci.
Encouraged by these earlier successes, we proceeded to carry out a larger meta-analysis of
six GWA datasets, including height association results for 15,821 individuals at ~2.2 million
SNPs, to find additional loci associated with height. Here we report the identification and
validation of ten newly identified associations between common SNPs and height variation
(each with P < 5 × 10-7), and an additional four associations with strongly suggestive
evidence (each with P < 5 × 10-6). We also confirm the two previously reported associations
(HMGA2 and GDF5-UQCC). The newly identified loci associated with height implicate
several biological pathways or gene sets—including targets of the let-7 microRNA,
chromatin remodeling proteins and Hedgehog signaling—as important regulators of human
stature. Finally, we examine the interaction with gender, test for epistatic interactions
between loci, and estimate the explanatory power of each locus individually and in
combination. These results broaden our understanding of the biological regulation of human
growth and set the stage for further genetic analysis of this classical complex trait.
RESULTS
Identification of loci associated with height
We carried out a meta-analysis of GWA data for height that included 15,821 individuals
from six studies: two type 2 diabetes case-control datasets (DGI4, n = 2,978; FUSION13, n
= 2,371), two nested cancer case-control datasets (NHS14, n = 2,286; PLCO15, n = 2,244)
and two datasets from population-based cohorts (KORA16, n = 1,644; SardiNIA17, n =
4,305)(Supplementary Table 1 online). All participants were of European ancestry. Because
genome-wide genotyping in these studies was done on different platforms (Affymetrix 500K
for DGI, KORA, and SardiNIA, Illumina 317K for FUSION and Illumina 550K for NHS
and PLCO), we imputed genotypes for all polymorphic markers in the HapMap Phase II
CEU reference panel in each GWA scan using the program MACH (Y. Li and G.R.A.,
unpublished data), thereby generating compatible datasets of 2,260,683 autosomal SNPs.
Adult height was tested for association with these SNPs in each study under an additive
genetic model, and association results were combined by meta-analysis using a weighted Z-
score method (Methods). Whereas the distribution of test statistics for each individual GWA
study was consistent with the expectation under the null hypothesis (Fig. 1), the quantile-
quantile plot of the meta-analysis results clearly showed a large excess of low P values at the
right tail of the distribution, despite minimal evidence of overall systematic bias (λGC =
1.089; Fig. 2a). This result suggests that true associations with height variation, which were
not discernable from the background in the individual studies, were brought to light in the
combined analysis. Indeed, the second- and third-strongest association signals in these
height meta-analysis results—HMGA2 rs1042725 (P = 2.6 × 10-11) and GDF5-UQCC
rs6060369 (P = 1.9 × 10-10)—have recently been shown to be robustly associated with
stature in humans not selected for tall or short stature11,12. These findings validate our
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meta-analytic approach and suggest that other loci associated with height are represented at
or near the top of our results.
To distinguish true variants associated with height from other SNPs that could have
achieved low P values by chance or confounding effects, and also to collect direct genotype
data for associations based on imputed genotypes, we set up a two-stage follow-up strategy
(Supplementary Fig. 1 online). In the first stage, we selected 78 SNPs representative of the
top association signals (ranked by P values, and taking into account linkage disequilibrium
(LD) to minimize redundancy); we then genotyped these 78 SNPs in a panel of European
Americans (n = 2,189) ascertained from the near-ends of the normal height distribution
(short, 5-10th percentile; tall, 90-95th percentile) (Supplementary Table 2 online). This
panel has been used previously to replicate very strongly the HMGA2 rs1042725
association12. To decrease the number of false positives taken into the second stage and
retain true associations with height, we selected for further study 29 SNPs that had an odds
ratio in the European American panel that was consistent with the direction of the effect
observed in the meta-analysis (Methods). We genotyped these SNPs in four large validation
(replication) panels: all 29 SNPs were genotyped in the population-based FINRISK97 cohort
(n = 7,803), and a subset was genotyped in the population-based KORA S4 (n = 4,130) and
PPP (n = 3,402) cohorts and the type 2 diabetes case-control FUSION stage 2 panel (n =
2,466) (Supplementary Tables 3-6 online). Because of logistic and technical issues, not all
29 SNPs could be genotyped in all four DNA panels, thus leading to a loss in power for
some of these SNPs in our follow-up strategy. Nevertheless, these combined efforts led to
the identification of 12 SNPs with combined P < 5 × 10-7 (using evidence from the meta-
analysis and the validation panels except the European American panel, because of its
specific ascertainment), a level of significance strongly suggestive of true association (Table
1; detailed association results and LD plots are given in Supplementary Table 7 and
Supplementary Fig. 2 online, respectively)3. Of the three loci with P values between 5 ×
10-7 and 5 × 10-8, two were confirmed in the accompanying manuscript18 (SH3GL3-
ADAMTSL3 and CDK6), and one had strong independent evidence of association in the
European American tall-short (USHT) panel (CHCHD7-RDHE2, P = 9 × 10-6; Table 1).
This indicates that loci with P values in this range are at least enriched for loci with valid
associations with height. In addition, four loci showed overall suggestive evidence
(combined P < 5 × 10-6) of association with adult height (Table 1). Although SNP
rs2730245 at the WDR60 locus has a combined P = 3 × 10-7, we chose to include this
marker in our list of suggestive associations because, unlike the 12 loci in the top section of
Table 1, this signal had a follow-up P > 0.05.
Characterization of signals associated with height
Population stratification is a possible strong confounder for association studies of height and
other human phenotypes19. We took several steps to ensure that the association signals for
height confirmed in our study were not due to population stratification. Association tests in
the NHS and PLCO datasets were corrected for residual population structure using principal
component methods20; a similar analysis on the unrelated component of DGI did not change
association results for the SNPs reported in Table 1 (Supplementary Table 8 online). An
analysis of the FINRISK97 replication panels stratified for geographic origins within
Finland did not alter the strength of the associations with height reported in Table 1
(Supplementary Table 9 online). Finally, using 279 variants known to correlate with the
major axes of ancestry in European-derived populations21, we calculated a small inflation
factor (λ) of 1.09 for our height meta-analysis results, suggesting that no substantial
stratification is shown even by markers selected for this purpose. Taken together, these
results indicate that the genetic associations with height found in our study are unlikely to be
due to population stratification.
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For the 16 SNPs identified with combined P < 5 ×10-6 (Table 1), there was, in the
FINRISK97 panel, no evidence of departure from an additive genetic model (P > 0.05 for
likelihood ratio test of additive versus unconstrained two degree-of-freedom test), no
significant difference in effect size between males and females (P > 0.05), and no strong
epistatic interactions between loci (the most significant interaction was observed between
SNP rs1492820 and SNP rs10946808 (P = 0.001), which is not significant after correcting
for the 120 pairwise tests of interaction done).
Explanatory power of loci associated with height
Each of the common height SNPs reported here explains a small fraction of the residual
phenotypic variation in height (0.1-0.8%; Supplementary Table 7). When analyzed together,
the additive effects of the 12 SNPs with combined P < 5 × 10-7 only contribute 2.0% of the
height variation in the FINRISK97 panel, far from the estimated ~80-90% attributable to
genetic variation. To assess the cumulative predictive value of this initial set of variants, we
created a ‘height score’ by counting the number of height-increasing alleles (12 SNPs;
height score 0-24) in each participant with complete genotype for these 12 SNPs in the
FINRISK97 panel (n = 7,566). On average, males and females with ≤8 ‘tall’ alleles (4.7% of
FINRISK97) are 3.5 cm and 3.6 cm shorter than males and females with ≥16 ‘tall’ alleles
(7.1% of FINRISK97), respectively (Fig. 3). Individual effect sizes range from 0.3 cm per T
allele for CDK6 rs2040494 to 0.5 cm per C allele for HMGA2 rs1042725 (Table 1).
DISCUSSION
Some of the SNPs reported here fall in or near strong candidate height genes, such as the
recently described associations with HMGA2 (ref. 12) and GDF5-UQCC11, whereas others
identify previously unsuspected loci. Together, these associations highlight biological
pathways that are important in regulating human growth.
Hedgehog-interacting protein (HHIP; rs1492820) is a transcriptional target and an
antagonist of Hedgehog signaling; it binds with high affinity to the three mammalian
Hedgehog proteins22. The mouse homolog, Hhip, is expressed in the perichondrium,
including regions flanking Indian hedgehog (Ihh) expression in the appendicular and axial
skeleton. Ectopic overexpression of Hhip in mouse cartilage causes severe skeletal defects,
including short-limbed dwarfism, a feature reminiscent of the phenotype observed in Ihh
null mice22,23.
We identified several associated SNPs in or near genes related to chromatin structure. In
addition to HMGA2, which encodes a chromatin-binding protein, we found associations
with a SNP (rs10946808) in a histone cluster on chromosome 6, a SNP (rs12986413) in the
histone methyltransferase DOT1L gene and a SNP (rs724016) in an intron of the methyl-
DNA-binding transcriptional repressor gene ZBTB38. It is currently unclear how genetic
variation at these loci modulate height, but there is a precedent for a connection between
regulation of chromatin structure and stature: Sotos syndrome (MIM117550), characterized
by extreme tall stature, is caused by mutations and deletions in the histone methyltransferase
gene NSD1. It would be interesting to test whether the height variants at HMGA2, the
chromosome 6 histone cluster, DOT1L and ZBTB38 modify clinical outcome in Sotos
syndrome, or whether severe mutations in these genes, particularly DOT1L, could cause a
Sotos syndrome-like phenotype.
That the variant rs1042725, strongly associated with adult and childhood height12, falls in
the 3′ UTR of HMGA2 is notable in part because HMGA2 is the human gene with the
greatest number of validated let-7 microRNA binding sites24,25. In fact, rs1042725 is 13
base pairs away from a let-7 site, suggesting a possible mechanism of action whereby the
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SNP alters microRNA binding and therefore expression of HMGA2. When we examined
our list of 12 height loci, we were somewhat surprised to find three additional previously
described targets of let-7: the cell cycle regulator CDK6 (ref. 26), the histone
methyltransferase DOT1L27 and the gene LIN28B28. PAPPA, a locus with a combined P =
1.2 × 10-6 in our study, also contains a predicted let-7 binding site27. Thus, genes that
influence height seem to be enriched for validated or potential let-7 targets: 5 of the 16
(31%) confirmed or suggestive loci associated with height have let-7 binding sites,
compared with 2% of the genes in the human genome (Fisher’s exact test P = 3 × 10-5).
Because microRNAs can co-regulate genes involved in the same biological process, it will
be interesting to test whether the other targets of let-7, or let-7 itself, are regulators of adult
height.
There were also noteworthy candidate genes among the variants that showed strong but as
yet less conclusive levels of significance for association with height in our meta-analysis of
GWA studies and replication cohorts. A SNP 28 kb upstream of PRKG2 (rs1662845), which
encodes the cGMP-dependent protein kinase II (cGKII), showed strong association with
height in our meta-analysis of GWA scans (P = 5.7 × 10-5), and in the same direction in the
European American height panel (P = 8.5 × 10-6) and the FUSION stage 2 sample (P =
0.001), but not in the FINRISK97 (P = 0.93, opposite direction) and PPP (P = 0.16, opposite
direction) panels. a This locus is very strong candidate for a role in height variation. First,
Prkg2-/- mice developed dwarfism that is caused by a severe defect in endochondral
ossification at the growth plates29. Second, the naturally occurring Komeda miniature rat
Ishikawa mutant, which has general longitudinal growth retardation, results from a deletion
in the rat gene encoding cGKII30. Therefore, in rodents, it is clear that cGKII has a role in
skeletal growth, acting as a molecular switch between chondrocyte proliferation and
differentiation. We predict that larger replication studies will demonstrate that common
genetic variation at the PRKG2 locus does contribute to height variation in humans, but it
seems possible that there will also be heterogeneity among studies.
Several newly identified loci associated with height are located near genes with less
immediately apparent connections to stature, including the G protein-coupled receptor gene
GPR126, a locus that encompasses the thyroid hormone receptor interactor TRIP11 and the
ataxin ATXN3 genes, a locus with the Huntingtin-interacting gene SH3GL3 and the
glycoprotein metalloprotease gene ADAMTSL3 (the later often mutated in colon cancer31),
a locus with gene CHCHD7, frequently fused to the PLAG1 oncogene in salivary gland
adenomas32, and the epidermal retinal dehydrogenase 2 gene RDHE2. Because of LD
(Supplementary Fig. 2), it is possible that the causal alleles at these loci are not located in
these genes; fine-mapping in larger cohorts or in populations of different ancestry may be
required to pinpoint the relevant gene and functional variant(s). Alternatively, these genes
may themselves influence height, and further work will be needed to elucidate the relevant
pathways and mechanisms.
We note that the accompanying manuscript by Weedon et al.18 identifies association with
height for several of the loci reported in our study (ZBTB38, HMGA2, GDF5-UQCC,
HHIP, SH3GL3-ADAMTSL3, CDK6), and reports, as we do, a suggestive association for a
SNP at the FUBP3 locus (P = 7.5 × 10-7 in our study; P = 2.0 × 10-5 in Weedon et al.).
FUBP3, a gene implicated in c-myc regulation, is therefore likely to represent an additional
locus associated with height.
The variants associated with height that we validated do not have strong enough effects to
generate detectable linkage signals33. Three of our loci lie under previously reported height
linkage peaks8: ZBTB38, lod score 2.03; TRIP11-ATXN3, lod score 2.01; and CDK6, lod
score 2.26. However, because 17.6% of the genome overlaps with a height linkage peak
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with lod score >2, the number of such co-localizations is not greater than expected by
chance (3 observed versus 2.12 expected). It remains possible that some genes harbor both
common and rare variants that influence height, so some overlaps may yet emerge between
associated and linked loci that have a real genetic basis. Furthermore, regions of linkage
may indicate the locations of rare variants or other types of genetic variation that are not
well captured by our current association methods.
As expected, the estimated effect sizes in the GWA meta-analysis were generally larger than
the effect sizes observed in replication samples, because of the well-known ‘winner’s curse’
phenomenon34. Perhaps less well appreciated is that the magnitude of the winner’s curse
effect depends on the underlying distribution of effect sizes: the greater the number of
variants with small effects, the more likely it is that one or more of these variants will
approach genome-wide significance even in a study that is not well powered to detect these
very modest effects35. Such variants will then prove difficult to convincingly replicate,
unless very large replication cohorts are used. Thus, it is possible that even some of the
initial associations that we failed to replicate will eventually be validated.
Given the modest effect sizes observed for the validated variants associated with height
(Table 1; average = 0.4 cm per additional allele), it is not surprising that the quantile-
quantile plots for the individual GWA studies are essentially indistinguishable from the null
expectation (Fig. 1). Indeed, we calculate that a study of 3,000 unrelated individuals has 1%
power to detect a variant (minor allele frequency 10%) that increases height by 0.4 cm at a
statistical threshold of P = 1 × 10-5. In comparison, a study of 16,000 individuals has 72%
power to identify the same variant (in fact, there is a slight loss in power when using meta-
analytic methods to combine results). Our discovery of valid associations by combining
individual studies with nearly null P-value distributions highlights the importance of using
large datasets to find common variants with small effects. When we remove the 12 validated
height variants (and nearby correlated SNPs) from the meta-analysis results, the number of
low P values still exceeds the null expectation (Fig. 2a, filled squares). Furthermore, the
10,000 SNPs with the best P values also showed excess evidence of association in an
independent meta-analysis18, even when all loci known to be associated with height were
excluded (Fig. 2b). These results indicate that there are other associations with common
alleles yet to be discovered, but that our meta-analysis is not sufficiently powered to identify
these associations because the effect sizes are small.
Our results have several implications. First, they outline a role for multiple genes and
biological pathways that were previously not known to regulate height, substantiating the
ability of unbiased genetic approaches to yield new biological insights. The identification of
these genes not only expands our knowledge of human growth but also promotes these
genes as candidates for as yet unexplained syndromes of severe tall or short stature. Second,
these findings convincingly confirm the polygenic nature of height, a classic complex trait,
and demonstrate that, at least for this trait, increasingly large GWA studies can uncover
increasing numbers of associated loci. Third, each variant makes only a small contribution to
phenotypic variation (although determining the total contribution of each of the loci reported
here requires much more comprehensive resequencing and genotyping); thus, either many
hundreds of common variants influence complex traits such as height and/or other genetic
contributors (for example, gene-gene or gene-environment interactions, rare variants with
large effects, or uncaptured genomic features such as structural polymorphisms) will play a
significant role. In particular, because the quality-control criteria used in the GWA studies
analyzed here would have removed SNPs affected by copy number polymorphisms, we
cannot conclude anything regarding the role of these variants on adult height. With the
development of new platforms and improved analytical tools applicable to large cohorts, it is
likely that the role of common structural variants on human complex traits such as adult
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height will soon be elucidated. Finally, if height is indeed a good model for other complex
traits, these results suggest that large meta-analyses of GWA studies will provide insights
not only into human growth but also into the underlying biological mechanisms of common
disease.
METHODS
Description of genome-wide association study samples
The individuals analyzed by the Diabetes Genetics Initiative (DGI) have been described
elsewhere4. In total, there were 1,464 type 2 diabetes cases and 1,467 matched controls of
European ancestry from Finland and Sweden. The Finland-United States investigation of
non-insulin-dependent diabetes mellitus genetics (FUSION) GWA study included 1,161
Finnish type 2 diabetes (T2D) cases, 1,174 normal glucose tolerant (NGT) controls, and 122
offspring of case-control pairs13. Cases and controls were matched as previously described,
taking into account age, sex and birth province within Finland. The KORA genome-wide
association study samples were recruited from the KORA S3 survey, which is a population-
based sample from the general population living in the region of Augsburg, Southern
Germany. The 1,644 study participants had a German passport and were of European
origin16. The Nurses’ Health Study (NHS) GWA scan included DNA from 2,286 registered
nurses of European ancestry: 1,145 postmenopausal women with invasive breast cancer and
1,142 matched controls14. The Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial (PLCO) GWA scan included 1,172 non-Hispanic prostate cancer cases of European
ancestry and 1,105 matched controls15. The SardiNIA GWAS examined a total of 4,305
related individuals participating in a longitudinal study of aging-related quantitative traits in
the Ogliastra region of Sardinia, Italy17. More details can be found in the Supplementary
Methods online.
Description of follow-up samples
The European American (n = 2,189) sample is a tall-short study with subjects ranking in the
5-10th percentiles in adult height (short women, 152-155 cm; short men, 164-168 cm) and in
the 90-95th percentiles in adult height (tall women, 170-175 cm; tall men, 185-191 cm)19.
All individuals were self-described ‘white’ or ‘of European descent’. All subjects were born
in the United States, and all of their grandparents were born in either the United States or
Europe. Using the Genetic Power Calculator36 and assuming a purely additive genetic effect
across the whole phenotypic distribution, we calculated that the study design of the
European American tall-short panel provides 33.0, 79.0 and 98.6% power to detect variants
that explain ≥0.1, 0.25 and 0.5% of the phenotypic variation in height, respectively (at an α-
threshold of 0.01), and power was greater to meet our less stringent screening criteria of any
odds ratio in the same direction than the effect observed in the meta-analysis. FINRISK
1997 is one of the population-based risk factor surveys carried out by the National Public
Health Institute of Finland every five years37, and was approved by the Ethical Committee
of the National Public Health Institute (decision number 38/96). The sample was drawn
from the National Population Register for five geographical areas. The FUSION stage 2
study includes a series of cases and controls matched to take into account age, sex, and birth
province within Finland13. The KORA S4 samples were recruited from Augsburg, Southern
Germany, and do not overlap with the KORA S3 population. Prevalence, Prediction and
Prevention of Diabetes (PPP) in the Botnia study is a population-based study started in 2004
to study the epidemiology of type 2 diabetes. More details can be found in the
Supplementary Methods. These studies were approved by the appropriate ethical review
boards.
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Because the GWA scans used different genotyping platforms, we imputed genotypes for all
polymorphic HapMap SNPs in each scan, using a hidden Markov model as implemented in
MACH (Y. Li and G.R.A., unpublished data). This approach allowed us to evaluate
association at the same SNPs in all scans. The imputation method combines genotype data
from each sample with the HapMap CEU samples (July 2006 phased haplotype release) and
then infers the unobserved genotypes probabilistically. The inference relies on the
identification of stretches of haplotype shared between study samples and individuals in
HapMap CEU reference panel. For each SNP in each individual, imputation results are
summarized as an ‘allele dosage’ defined as the expected number of copies of the minor
allele at that SNP (a fractional value between 0.0 and 2.0). As previously described, r2
between each imputed genotype and the true underlying genotype is estimated and serves as
a quality-control metric (rsq_hat in Supplementary Table 7). We chose an estimated r2 >0.3
as a threshold to flag and discard low-quality imputed SNPs (ref. 13 and Y. Li and G.R.A.,
unpublished data).
Association analyses
For all studies, except for the European American height panel, we converted height to Z
score, taking into account sex, age and disease status when appropriate. For the DGI, KORA
S3, NHS, PLCO, FINRISK97, KORA S4 and PPP cohorts, we carried out association
testing using a regression framework implemented in PLINK38 for genotyped markers, and
in MACH2QTL (Y. Li and G.R.A., unpublished data), which takes into account dosage
information (0.0-2.0), for imputed SNPs. For DGI, we used a genomic control method to
correct for the presence of related individuals. Association testing in the FUSION and
SardiNIA datasets was done for both genotyped and imputed SNPs using a method that
allows for relatedness, estimating regression coefficients in the context of a variance
components model39. Statistical analysis for the European American tall-short panel was
done using a Cochran-Mantel-Haenszel (CMH) test38 stratified by the European region of
origin of the grandparents.
Meta-analysis
Association results presented in this manuscript take into account the posterior probability
on each imputed genotype. To combine results, we used a weighted Z-score method:
zw is the weighted Z score from which the meta-analytic two-tailed P value is calculated, zi
is the Z score from study i (calculated as the cumulative normal probability density for the
corresponding one-tailed P value, adjusted if needed by subtracting the P value from one
when the direction of the effect is reversed), Ni is the sample size of study i and Ntot is the
total sample size. In total, we combined association results at 2,260,683 autosomal SNPs in
15,821 individuals (DGI, n = 2,978; FUSION, n = 2,371; KORA, n = 1,644; NHS, n =
2,286; PLCO, n = 2,244; SardiNIA, n = 4,305). The I2 statistic40 and Cochran’s Q test were
used to assess heterogeneity.
Genotyping and quality control
Genotyping of the initial GWA studies is described elsewhere4,11,13-15, except for KORA,
which is described in the Supplementary Methods. Genotyping in the European American
height panel and the replication panels FINRISK97, PPP, FUSION stage 2 and KORA S4
was done using the Sequenom MassARRAY iPLEX platform. From the meta-analysis, we
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selected 78 SNPs (three iPLEX pools; six SNPs failed) for genotyping in the European
American tall-short panel (n = 2,189): SNPs were first ranked using their meta-analytic P
values, and then binned using the LD pattern from the HapMap Phase II CEU population
(SNPs with r2 >0.5 to a SNP with a lower P value were binned together with that SNP).
When a locus had more than one high-ranking bin, we only genotyped the most significant
SNP such that only one SNP per locus or gene was genotyped. Because of the specific
design of this DNA panel (near-ends of the height distribution) but also because effect sizes
on height are small (and were inflated by the winner’s curse in the meta-analysis), we
promoted for genotyping in larger follow-up cohorts markers that had an odds ratio
consistent with the direction of the effect observed in the meta-analysis (without considering
the magnitude of the European American CMH P values). For the FINRISK97 panel, 29
SNPs were attempted and two failed. For the PPP panel, 23 SNPs were attempted and two
failed. For the FUSION stage 2 panel, 27 SNPs were attempted and one failed. For the
KORA S4 panel, five SNPs were attempted and one failed. For all passing SNPs, the
genotyping success rate was >96% and the consensus error rate, estimated from replicates,
was <0.1%.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Quantile-quantile plot of ~2.2 million SNPs for each of the six genome-wide association
scans meta-analyzed. (a) DGI (n = 2,978). (b) FUSION (n = 2,371). (c) KORA (n = 1,644).
(d) NHS (n = 2,286). (e) PLCO (n = 2,244). (f) SardiNIA (n = 4,305). Each black circle
represents an observed statistic (defined as the -log10(P)) versus the corresponding expected
statistic. The gray line corresponds to the null distribution.
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Quantile-quantile plots supporting the presence of additional loci associated with height. (a)
Plot of 2,260,683 SNPs from the meta-analysis of the six GWA scans (n = 15,821). Each
black triangle represents an observed statistic (defined as the -log10(P)) versus the
corresponding expected statistic. The black squares correspond to the distribution of test
statistics after removing markers correlated to the 12 height signals with P < 5 ×10-7
described in Table 1. The gray line corresponds to the null distribution. (b) Association
results from Weedon et al.18 provide independent evidence that the top 10,000 SNPs from
our meta-analysis exceed the null expectations (gray line). We selected the top 10,000 SNPs
from our meta-analysis before (black triangles) and after (black squares) removing SNPs
marking the known height loci (identified by us and in the accompanying manuscript) and
retrieved the corresponding P values from Weedon et al. We show one-tailed P values
because we corrected for the direction of effects, if needed. Inflation factors are unusually
high because the analysis is restricted to the top 10,000 SNPs, which are likely enriched for
SNPs that are truly associated with height variation.
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Analysis of combined effects. For each participant in the FINRISK97 panel with complete
genotype at the 12 SNPs with P < 5 × 10-7 in Table 1 (n = 7,566), we counted the number of
height-increasing alleles to create a height score. Individuals with ≤8 or ≥16 ‘tall’ alleles
were grouped. For each height score group, in men and women separately, the mean ± 95%
confidence interval is plotted. The axis for men is on the left and the axis for women is on
the right (same scale). The regression line in dark gray indicates that, for both men and
women, each additional ‘tall’ allele increases height by 0.4 cm. The light gray histogram in
the background represents the relative fraction of individuals in each height score group
(height score ≤8: 4.7%; height score 9: 6.2%; height score 10: 11.1%; height score 11:
15.5%; height score 12: 17.5%; height score 13: 15.6%; height score 14: 13.7%; height
score 15: 8.6%; height score ≥16: 7.1%).
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